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description of statin use in reﬁll claims data. DISCLOSURE:
Pﬁzer Inc. provided access to the Protocare database and ﬁnan-
cial support for drawing the initial sample. Kochevar and
Williams have received past support from Pﬁzer Inc. but not for
this analysis.
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OBJECTIVE: Medication adherence is a recognized problem in
older persons and is exacerbated by the factors such as comor-
bid conditions. The aim of this study was to examine the rela-
tionship between self-reported health status and medication
adherence in older adults with chronic diseases. METHODS: A
longitudinal cohort study was conducted in older adults (aged
greater than or equal to 65 years) enrolled in a health mainte-
nance organization. Study sample included patient cohorts with
four major chronic diseases: Type 2 Diabetes Mellitus (n = 667),
Overactive Bladder (n = 176), Asthma (n = 129), and Psoriasis
(n = 63). Self-reported health perception, falls, lifestyle, and
depressive symptomatology in the pre-enrollment year were mea-
sured using a risk-assessment questionnaire. The SF-12 ques-
tionnaire assessed the quality of life and the short-form Center
for Epidemiologic Studies Depression Scale assessed depression
level (0–100). Medication Possession Ratio (MPR) was used as
a measure of medication adherence. Multivariate regression
analyses were conducted examining predictors of MPR scores.
RESULTS: A 0.28-point increase in MPR [Range 0–1] was found
in patients receiving oral antidiabetics as compared to patients
who did not receive oral antidiabetics (p < 0.001). Increased
number of comorbidities were associated with decreased adher-
ence (p < 0.05). In OAB patients, previous year hospitalization
was associated with 0.05-point decrease in MPR for antimus-
carinic medication (p < 0.05). For asthmatic patients, depressive
symptomatology was associated with 0.31-point decrease in
MPR (p < 0.05). Psoriasis patients with depressive symptoms and
those whose physical activity was only moderate were less adher-
ent to topical corticosteroids (both p < 0.01). CONCLUSION:
Signiﬁcant associations were found between predictors of health
status such as depressive symptoms and decreased medication
adherence in elderly patients with chronic diseases. Health status
assessments completed at the time of enrollment may have the
potential to identify older adults at risk for poor adherence for
better intervention.
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OBJECTIVES: Poor adherence to antiviral therapy in hepatitis
C virus (HCV) patients is a well-documented problem. The Be
In Charge® program (BIC) is a comprehensive patient support
program that encourages adherence by providing 24-hour
inbound and proactive outbound telephone nursing support and
mailings of HCV educational materials throughout therapy. The
purpose was to determine the impact of BIC on patient 
adherence to peginterferon alfa-2b combination therapy (peg-
2b). METHODS: A retrospective cohort analysis compared BIC
enrollees to propensity-score matched peg-2b starters not
enrolled in BIC (controls). Subjects were included if they were
≥18 years of age; started peg-2b on or after January 1, 2004;
and could be observed for at least 12 weeks after treatment ini-
tiation. Adherence was measured as the number of injections dis-
pensed and proportion of patients who received an average of
≥1 injection per week during follow-up. Adherence was com-
pared using paired chi-square and t-test. RESULTS: After match-
ing, each cohort consisted of 780 eligible subjects observable 
for ≥12 weeks; 638 and 333 subjects in each cohort were 
observable for 24 and 48 weeks, respectively. BIC subjects
reﬁlled 1.2 more injections (95% conﬁdence interval [CI] 0.52,
1.83; P < 0.0001) than the control cohort within 12 weeks, 2.7
more (95% CI 1.5, 3.8; P < 0.0001) within 24 weeks, and 6.7
more (95% CI 4.3, 9.1; P < 0.0001) within 48 weeks. Addi-
tionally, BIC enrollees were more likely to reﬁll ≥12 injections
within 12 weeks of initiation (72% vs. 64%, P = 0.0005), ≥24
injections within 24 weeks (52% vs. 41%, P < 0.0001), and ≥48
injections within 48 weeks (22% vs. 13%, P = 0.0020). CON-
CLUSION: This quasi-experimental study suggest the BIC
program signiﬁcantly improved adherence to peg-2b. Additional
research is needed to ascertain which aspects of the program are
most effective and which patients are most likely to beneﬁt from
this intervention.
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OBJECTIVES: The primary objective of this project is to assess
the prevalence of medication compliance and persistency with
specialty medications in patients newly diagnosed with speciﬁc
disease conditions such as Growth Hormone (GH), Chronic
Hepatitis C (CHC), Multiple Sclerosis (MS) and Rheumatoid
Arthritis (RA). METHODS: For each disease condition, separate
cohorts of patients who were newly diagnosed between May 1,
2004 and August 1, 2004 time periods were identiﬁed and
selected using PBM pharmacy claims database. Patients were
deﬁned as new to therapy if they were not prescribed the same
specialty medication six months prior to the study period.
Patients who lost prescription drug beneﬁt eligibility during the
study period were excluded from analysis. Identiﬁed patients
were then followed for a period of 12 months from the treat-
ment start date. Compliance was measured by computing the
Medication Possession Ratio (MPR), which is deﬁned as the ratio
of the total days supply obtained to the total number of days in
the study period. Persistency was reported in terms of average
length of therapy in days. The compliance and persistency mea-
sures were also controlled for differences in gender and age.
RESULTS: The mean MPR was 0.66 for patients on GH (N =
60), it was 0.48 for patients on CHC (N = 107, 0.65 on MS (N
= 173) and 0.63 on RA (N = 324). The average length of therapy
for patients on GH was 274. 5 days, on CHC was 196.0, on MS
was 270.1 days and on RA was 285.2 days. CONCLUSIONS:
Non-compliance and non-persistency is a critical and prevalent
problem in the patients taking specialty medications. Disease
speciﬁc efforts are needed to improve medication compliance and
persistency to optimal level in order to achieve effective treat-
ment outcomes.
